OPTN Stock Price, Chart, Stats & News
OptiNose, Inc. (OPTN) does not currently pay a dividend.
OPTN chart
Price history is unavailable
We don't have enough price data for OPTN to draw a chart yet.
Fundamentals
Gross margin | 90.60% |
Operating margin | -15.13% |
Pretax margin | -36.35% |
Net margin | -36.35% |
Effective tax rate | – |
ROA | -19.42% |
ROE | 46.86% |
D/E | -2.07x |
Interest coverage ratio | -0.62x |
OPTN valuation
P/E | – |
P/S | 1.58x |
P/B | -1.83x |
P/CF | -6.05x |
P/FCF | -5.25x |
P/OCF | -6.05x |
PEG | 2.63x |
EV multiple | 15.05x |
About
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment.
Similar securities
Based on sector and market capitalization
